Zobrazeno 1 - 10
of 176
pro vyhledávání: '"B. Lathan"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hans-Henning Flechtner, Andreas Josting, P. Tralls, Volker Diehl, M. Sieber, B. Lathan, J.-U. Rüffer
Publikováno v:
European Journal of Cancer. 39:2179-2186
Although treatment regimens for Hodgkin's lymphoma have become more sophisticated, little is known about the prevalence of fatigue in long-term survivors. Therefore, we investigated the fatigue status of long-term survivors of Hodgkin's lymphoma and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e8d04be085fd2ef3771ad97b3a1ad25
https://doi.org/10.1016/s0959-8049(03)00545-8
https://doi.org/10.1016/s0959-8049(03)00545-8
Autor:
E. Duehmke, Peter Koch, Richard Greil, Jeremy Franklin, M. Sieber, Jürgen Wolf, Markus Loeffler, Dirk Hasenclever, Andreas Engert, Axel Georgii, Anselmo Ap, Andreas Josting, Michael Pfreundschuh, Beate Pfistner, Reinhold Munker, Hans Tesch, Volker Diehl, Gottfried Doelken, B. Lathan, Klaus-Peter Schalk, Richard Herrmann, Hartmut Kirchner, Oana Brosteanu, Ursula Paulus, U. Rueffer, T. Koch
Publikováno v:
Journal of Clinical Oncology. 20:476-484
PURPOSE: To investigate whether treatment results in intermediate-stage Hodgkin’s lymphoma can be improved by rapid application of non–cross-resistant drugs, the 10-drug regimen cyclophosphamide, vincristine, procarbazine, and prednisone (COPP),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba032bbf0313e57c998d684bcf7fe470
https://doi.org/10.1200/jco.2002.20.2.476
https://doi.org/10.1200/jco.2002.20.2.476
Autor:
Kai Breuer, Juergen Wolf, Andreas Engert, H. Nisters-Backes, Oliver Manzke, U. Rueffer, Hans Tesch, Volker Diehl, Henning Bredenfeld, F. J. Grotenhermen, B. Lathan, Andreas Josting, M. Sieber, Peter Koch
Publikováno v:
Annals of Oncology. 12:1307-1311
UNLABELLED Infertility after treatment of patients with Hodgkin's disease (HD) is considered as a side effect of alkylating agent containing chemotherapy regimens. To investigate whether gonadal failure is related primarily to the toxic effect of che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93e2f6a749b5ffd2259d1cb5a874d554
https://doi.org/10.1023/a:1012464703805
https://doi.org/10.1023/a:1012464703805
Autor:
Norman Willich, Michael Pfreundschuh, Dirk Hasenclever, Andreas Engert, U. Rüffer, Eckhart Dühmke, Susanne Staar, Adelheid Emminger, Richard Greil, Esther Fritsch, Anton Atzinger, Maria K. Beykirch, Ursula Paulus, Susanne Sehlen, Richard Herrmann, B. Lathan, Jürgen Wolf, Axel Georgii, U. Rühl, Peter Lukas, Oana Brosteanu, M. Sieber, Peter Koch, Volker Diehl, Angelika Drochtert, Rolf-Peter Müller, Markus Loeffler, Jeremy Franklin, Hartmut Kirchner
Publikováno v:
Journal of Clinical Oncology. 19:2905-2914
PURPOSE: To show that radiotherapy (RT) dose to the noninvolved extended field (EF) can be reduced without loss of efficacy in patients with early-stage Hodgkin’s disease (HD). PATIENTS AND METHODS: During 1988 to 1994, pathologically staged patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a1eeffa62c80a8d430bcf8de52fef85
https://doi.org/10.1200/jco.2001.19.11.2905
https://doi.org/10.1200/jco.2001.19.11.2905
Autor:
Peter Koch, M Sextro, D. Hasenclever, Jeremy Franklin, Michael Pfreundschuh, H. Kirchner, B. Lathan, Hans Tesch, U. Rueffer, Volker Diehl, G. Ehninger, N. Schmitz, M. Loeffler
Publikováno v:
Annals of Oncology. 12:471-477
Summary Background The magnitude of chemotherapy dose escalation made possible by the use of recombinant haematopoietic growth factors has not been quantified in a randomized trial Patients and methods Patients with refractory or relapsing Hodgkin’
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4546e9b95a48a879aea192c6375ce0c9
https://doi.org/10.1023/a:1011108722666
https://doi.org/10.1023/a:1011108722666
Autor:
Burkhard Haastert, Annette Sauer, Roja Wahdat, Christian A. Lerchenmuller, B. Lathan, Ulrich Germing, H. Tilman Steinmetz, Stephan Schmitz, Hans Tesch
Publikováno v:
Blood. 128:4333-4333
The international prognosis scoring system (IPSS) and the revised-IPSS were generated with data from 816 and 7,019 patients (pts) from academic centers with a median age of 69 and 71 years (y) respectively. As the median age of pts with MDS receiving
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1695bee10b7de4b418b378f3f3151a8
https://doi.org/10.1182/blood.v128.22.4333.4333
https://doi.org/10.1182/blood.v128.22.4333.4333
Autor:
C. Tirier, N. Schmitz, M. Loeffler, G. Schwieder, Jeremy Franklin, Hans Tesch, Volker Diehl, Dirk Hasenclever, U. Rüffer, Andreas Engert, M. Sieber, U. Müller, Gottfried Dölken, Gerald Wulf, Michael Pfreundschuh, P. Worst, B. Lathan, Peter Koch, U. Bruntsch, Klaus-Peter Schalk
Publikováno v:
Scopus-Elsevier
The BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen, a rearranged and accelerated version of the standard COPP/adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy, ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91b2d2fb663f1625e6f2fa4f5d9805bc
https://doi.org/10.1182/blood.v92.12.4560
https://doi.org/10.1182/blood.v92.12.4560
Autor:
K von Kalle, D. Hasenclever, Jeremy Franklin, Michael Pfreundschuh, A. Glunz, C Haedicke, R. Hermann, Axel Georgii, J.-U. Rüffer, Helge Bischoff, Juergen Wolf, Andreas Engert, M Sextro, Ursula Paulus, Hans Tesch, Gerald Wulf, Eckhart Dühmke, U Stappert-Jahn, L Holmer, E Winnerlein-Trump, M. Loeffler, Volker Diehl, Stefan W. Krause, M. Sieber, B. Lathan
Publikováno v:
Annals of Oncology. 9:s67-s71
The BEACOPP chemotherapy regimen for advanced Hodgkin's disease employs a rearranged schedule permitting a shortened three-week cycle. With haematological growth factor support, the dosages of cyclophosphamide, etoposide and adriamycin could be moder
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cba6da4240336077287408804b3fc04
https://doi.org/10.1093/annonc/9.suppl_5.s67
https://doi.org/10.1093/annonc/9.suppl_5.s67
Autor:
M. Adler, Michael Pfreundschuh, D. Hasenclever, Hans Tesch, Volker Diehl, M. Sieber, Peter Koch, U. Rüffer, B. Lathan, M. Loeffler, D. Lieberz
Publikováno v:
Annals of Oncology. 8:143-148
Summary Purpose At present, treatment results for patients with advanced-stage Hodgkin's disease remain unsatisfactory. Standard chemotherapy M(C)OPP (nitrogen mustard (cyclophosphamide), vincristine, procabazine, and prednisone), ABVD (adriamycine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53a02342b960a14d99a29e180852dd70
https://doi.org/10.1023/a:1008294312741
https://doi.org/10.1023/a:1008294312741